GlobeNewswire

Progress and Potential for Achieving Cleaner Air on a Global Basis

Dela

Adoption of New Generation Diesel Technology Delivers Rapid Clean Air Benefits 

New understanding of global air quality highlights the need for technologies like new-generation diesel engines, which are capable of accelerating emissions reductions

WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Recent reports highlighting air quality conditions in the United States (State of the Air) and globally (State of Global Air 2018) celebrate the progress made in developed and developing countries, but also emphasize significant disparities in progress toward reducing levels of key pollutants such as particulate matter and ozone.

"Achieving continued clean air progress while also sustaining economic growth is possible. Cities and countries must move to proven cleaner engines and fuels," said Allen Schaeffer, executive director of the Diesel Technology Forum. "We can and should bring the tremendous benefits of new technology diesel engines to communities and countries large and small around the world so they too can reduce emissions while efficiently building their economies and infrastructure, improving the quality of life for people everywhere."

"While it is surprising the extent that particulate matter from household cooking and non-transportation sources contributes to the health burden in the new report, the opportunities for reducing fine particle emissions from the motor vehicle and industrial engine segments are also part of the solution," said Schaeffer. "Worldwide harmonization of fuel quality and vehicle engine emissions standards would leverage the societal benefits of new diesel technology to more users around the world."

For example: Today, nearly one in every two trucks on the road in the United States are equipped with fine particle- and smog-reducing advanced clean diesel technology. In the most comprehensive study conducted on these engines, The Health Effects Institute found "substantial emissions and health benefits from US 2007/2010 and Euro VI/6 engines," demonstrating "dramatic improvements in emissions and the absence of any significant health effects."

In 2000, the U.S. Environmental Protection Agency (EPA) challenged diesel engine and truck manufacturers to achieve near-zero emissions in their products by 2010, with diesel off-road equipment manufacturers targeting 2014. Following a switch to ultra-low-sulfur diesel fuel in 2006, today's industry has not only met the near-zero challenge, but is well into the second and third generations of new diesel technologies. The industry continues to build on this success by seeking lower greenhouse gas emissions and greater fuel efficiency for the diesel engine.

The societal benefits of these efforts are now clear: According to the American Lung Association's analysis, ".the best progress [in 2018] came in the continued reduction of year-round particle pollution, thanks to cleaner power plants and increased use of cleaner vehicles and engines."

"Clean diesel technology plays an increasing role in helping cities, states and countries achieve cleaner air quality worldwide," said Schaeffer. "The latest generation diesel engines - ones that use selective catalytic reduction systems and diesel particulate filters - offer near-zero particulate matter (PM) and nitrogen oxides (NOx) emissions. With such technology, NOx emissions can be reduced by up to 90 percent while simultaneously reducing hydrocarbon and carbon monoxide emissions by 50-90 percent, and PM emissions by 30-50 percent. Ultra-low-sulfur diesel fuel immediately cuts soot emissions from diesel vehicles and equipment by 10 percent."

The State of Global Air 2018, compiled by The Health Effects Institute, the Institute for Health Metrics and Evaluation at the University of Washington, and the University of British Columbia, dramatically expands our understanding of all the sources that contribute to fine-particle air pollution; this was identified as the greatest environmental risk factor worldwide. Ninety-five percent of the world's population lives in areas exceeding the World Health Organization's (WHO) guideline for healthy air, and nearly 60 percent live in areas that do not meet even the WHO's least-stringent air quality target.

"Global considerations of air quality improvement must go beyond the road transport sector because diesel engines not only power the majority of commercial vehicles, but also nearly all marine and rail, industrial, agricultural and construction machines and equipment," said Schaeffer. "Similar clean diesel technologies that reduce fine particle emissions from commercial vehicles are now available in these large engine applications."

About The Diesel Technology Forum
The Diesel Technology Forum is a non-profit organization dedicated to raising awareness about the importance of diesel engines, fuel and technology. Forum members are leaders in clean diesel technology and represent the three key elements of the modern clean-diesel system: advanced engines, vehicles and equipment, cleaner diesel fuel and emissions-control systems. For more information, visit  http://www.dieselforum.org .

Connect with the Diesel Technology Forum
For the latest insights and information from the leaders in clean diesel technology, join us on Facebook, follow us on Twitter @DieselTechForum, or YouTube @DieselTechForum and connect with us on LinkedIn. Get it all by subscribing to our newsletter Diesel Direct for a weekly wrap-up of clean diesel news, policy analysis and more direct to your inbox.

Contact:
Sarah Dirndorfer
sdirndorfer@dieselforum.org
301.668.7230 (o) 301.706.8276 (c)




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Diesel Technology Forum via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum